These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15334753)

  • 1. Comparison of heparin administration using the Rapidpoint Coag and Hepcon HMS.
    Newsome J; Stipanovich K; Flaherty S
    J Extra Corpor Technol; 2004 Jun; 36(2):139-44. PubMed ID: 15334753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X.
    Hardy JF; Bélisle S; Robitaille D; Perrault J; Roy M; Gagnon L
    J Thorac Cardiovasc Surg; 1996 Jul; 112(1):154-61. PubMed ID: 8691862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system].
    Sakurada T; Kikuchi Y; Koushima R; Nakashima S; Hachiro Y; Kagaya H
    Nihon Kyobu Geka Gakkai Zasshi; 1997 Jun; 45(6):836-40. PubMed ID: 9217380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery.
    Ichikawa J; Kodaka M; Nishiyama K; Hirasaki Y; Ozaki M; Komori M
    J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1003-7. PubMed ID: 24508375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis With Heparin During Orthotopic Liver Transplantation: Comparison of Hepcon HMS Plus and Anti-Xa Assays for Low-Range Heparin.
    Nicolau-Raducu R; Occhipinti E; Marshall T; Koveleskie J; Ganier D; Evans B; Daly W; Fish B; Cohen AJ; Reichman TW; Bruce D; Bohorquez H; Seal J; Ahmed E; Carmody I; Loss G; Rayburn J; Nossaman B
    J Cardiothorac Vasc Anesth; 2017 Apr; 31(2):575-581. PubMed ID: 27745797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device.
    Noui N; Zogheib E; Walczak K; Werbrouck A; Amar AB; Dupont H; Caus T; Remadi JP
    Perfusion; 2012 May; 27(3):214-20. PubMed ID: 22301392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass.
    Gruenwald C; de Souza V; Chan AK; Andrew M
    Perfusion; 2000 Jun; 15(3):203-9. PubMed ID: 10866421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
    Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
    Murray DJ; Brosnahan WJ; Pennell B; Kapalanski D; Weiler JM; Olson J
    J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time.
    Raymond PD; Ray MJ; Callen SN; Marsh NA
    Perfusion; 2003 Sep; 18(5):269-76. PubMed ID: 14604242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass.
    Machovec KA; Jooste EH; Walczak RJ; Homi HM; Jaquiss RD; Lodge AJ; Ames WA
    Paediatr Anaesth; 2015 Jun; 25(6):580-6. PubMed ID: 25530420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.